As a result of promising data from its Phase Ib/II KEYNOTE-365 trial, Merck...
- Merck initiates three Phase III trials into Keytruda for prostate cancer
- Erectile dysfunction: giving patients more choice and better treatments
- AbCellera and Novartis enter into multi-target partnership
- FDA grants Merck’s Keytruda priority review as first line therapy for HNSCC
- ICR unveils efficacious cancer drug with new mechanism of action
The world is getting better, look no further than vaccines
GlobalData believes that the V920 vaccine is likely to be approved by the FDA this year and will establish a market-leading position in Ebola prevention.
Merck initiates three Phase III trials into Keytruda for prostate cancer
As a result of promising data from its Phase Ib/II KEYNOTE-365 trial, Merck has announced three new Phase III trials into the safety and efficacy of Keytruda (pembrolizumab) for patients with metastatic castration-resistant prostate cancer (mCRPC).
AstraZeneca hopes FDA breakthrough therapy can rise above a string of recent failures
A respiratory syncytial virus is a common pneumovirus that causes seasonal lung and respiratory tract infections across the globe.
Eli Lilly poised to shake-up atopic dermatitis market with first oral treatment
Atopic dermatitis is the result of a complex interplay of environmental, immunological, genetic and pharmacological factors.
Erectile dysfunction: giving patients more choice and better treatments
Erectile dysfunction affects around 50% of men between 40 and 70 years old. Futura Medical is currently developing a topical gel product, named MED2005, as a new therapeutic approach for the condition. Can MED2005 add to the treatment choices in the erectile dysfunction space?
AbCellera and Novartis enter into multi-target partnership
Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis under which its antibody discovery technology will be leveraged by the Swiss pharma giant for up to ten clinically-relevant disease targets.
Checkered data hinders Reata’s bardoxolone Phase II prospects
Creatinine is a waste product that is filtered through the kidneys and excreted in urine. Doctors measure blood creatinine levels to test kidney function.
FDA grants Merck’s Keytruda priority review as first line therapy for HNSCC
Merck has announced the US Food and Drug Administration (FDA) has granted priority review for its supplementary biologics license application (sBLA) for Keytruda as first line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.